SCLEROFOAM: Efficacy and Safety of Polidocanol Foam 3% in the Treatment of II Degree Hemorrhoidal Disease

Sponsor

Societa Italiana di Chirurgia ColoRettale (Other)

Overall Status

Completed

CT.gov ID

NCT03791775

Collaborator

SICCR - Gaetano Gallo (Other)

183

Enrollment

Location

Arm

Actual Duration (Months)

10.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Hemorrhoidal disease (HD) is one of the oldest and most common proctologic diseases that has been described with an estimated prevalence between 4.4% and 86%. Despite the proposal of three mechanisms that might underlie haemorrhoidal development - the varicose vein theory, the vascular hyperplasia theory and the sliding anal-lining theory, the exact pathophysiology of symptomatic hemorrhoid disease is poorly understood.

HD seems to be the most common cause for rectal bleeding, or hematochezia, and the second most frequent cause for severe rectorrhagia after diverticulitis. The blood is bright red and coats the stool at the end of defection. Other symptoms include pain, mucous discharge, itching or the sensation of tissue prolapse.

The most widely accepted classification is the Goligher classification:

Grade I: hemorrhoids bleed but do not prolapse out of the anal canal;
Grade II: hemorrhoidal cushions prolapse outside of the anal canal on straining or during bowel movements, but reduce spontaneously;
Grade III: hemorrhoidal cushions prolapse outside the anal canal on straining and require manual reduction;
Grade IV: hemorrhoidal prolapse is irreducible even with manipulation

Condition or Disease	Intervention/Treatment	Phase
Second-degree Hemorrhoids	Drug: Polidocanol foam (Atossisclerol® 3%)	Phase 2

Detailed Description

As reported by the guidelines of the Italian Society of Colorectal Surgery, in case of failure of conservative therapies the most common outpatient treatments for first- and second-degree Hemorrhoidal Disease (HD) are rubber band ligation and sclerotherapy.

Sclerotherapy causes an inflammatory reaction with local sclerosis of the submucosal tissue and a consequent fixation of the haemorrhoidal tissue to the underlying tissue. Moreover, the effect of sclerosing solutions is that of making vascular damage via producing endothelial injury.

A 100% improvement in bleeding was reported in patients with II and grade III hemorrhoids, and a complete resolution of the condition was described in 69% of non-selected patients, 52% in grade III and 88% in grade I. Resolution of prolapse was reported in 90-100% of patients affected by grade II hemorrhoids. Complications are rare but serious, and include impotence, irreversible necrotizing fasciitis and abdominal compartment syndrome [31-33]. In Germany, sclerotherapy with liquid agents is considered the first choice in treating grade I hemorrhoids. The only approved medical product by German authorities is polidocanol (Lauromacrogol 400 (INN), H3C-(CH2)11-(O-CH2-CH2)n∼9-OH), produced by Chemische Fabrik Kreussler & Co. GmbH.

In Italy, this drug is known as Atossisclerol 3%. The polidocanol is a non-ionic detergent made up of a chain of hydrophilic polyethylene oxide mixed with aliphatic hydrophobic dodecyl alcohol and it is recommended for first- and second-degree HD. The effects of polidocanol are similar to those of phenol oil but less number of side effects.

Based on these experiences, Karl-Heinz Moser introduced the use of polidocanol foam in the treatment of grade I hemorrhoids. In 2013, the same author published the results of a randomized, controlled, single blind, multicentre trial on the efficacy and safety of sclerotherapy with polidocanol foam in comparison with liquid sclerosant agents in treating grade I hemorrhoids [28]. In the foam group success rate after one sclerotherapy session was 88%, while success rate among patients treated with liquid polidocanol was 69%. Furthermore, patients treated with foam were more satisfied than those treated with liquid polidocanol (99% vs. 84% p=0.009). Finally, the quantity of polidocanol injected in the foam group was significantly lower (p<0.001), as well as the number of sessions requested (p<0.001).

In summary, according to the authors, these results suggest that polidocanol foam can be used as the treatment of choice in grade I HD.

The aim of this study is to evaluate the efficacy and safety of sclerotherapy with 3% polidocanol foam (PF) on patients affected by second-degree HD.

Study Design

Study Type:

Interventional

Actual Enrollment :

183 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

Patients enrolled in the study, according to the inclusion and exclusion criteria, will undergo sclerotherapy performed with polidocanol foam (Atossisclerol® 3%, Chemische Fabrik Kreussler & Co. GmbH, Wiesbaden, Germany). The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleedingPatients enrolled in the study, according to the inclusion and exclusion criteria, will undergo sclerotherapy performed with polidocanol foam (Atossisclerol® 3%, Chemische Fabrik Kreussler & Co. GmbH, Wiesbaden, Germany). The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Multicentre, Open-label, Single-arm Phase II Trial on the Efficacy and Safety of Sclerotherapy Using 3% Polidocanol Foam to Treat Second-degree Hemorrhoidal Disease

Actual Study Start Date :

Jan 2, 2019

Actual Primary Completion Date :

Jun 2, 2019

Actual Study Completion Date :

Jun 2, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Polidocanol 3% Foam Patients enrolled in the study, according to the inclusion and exclusion criteria, will undergo sclerotherapy performed with polidocanol foam (Atossisclerol® 3%, Chemische Fabrik Kreussler & Co. GmbH, Wiesbaden, Germany).	Drug: Polidocanol foam (Atossisclerol® 3%) The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding

Arm

Intervention/Treatment

Experimental: Polidocanol 3% Foam

Drug: Polidocanol foam (Atossisclerol® 3%)

The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding

Outcome Measures

Primary Outcome Measures

Success Rate 1 [12 months follow-up]
To establish the success rate after one sclerotherapy session, in terms of complete resolution of bleeding episodes one week after the injection Bleeding will be assessed using both the Hemorrhoidal Disease Symptoms Score and the Giamundo score. Rørvik HD et al (2019) Hemorrhoidal Disease Symptom Score and Short Health ScaleHD: New Tools to Evaluate Symptoms and Health-Related Quality of Life in Hemorrhoidal Disease. Dis Colon Rectum; 62:333-342 Giamundo et al (2018) Doppler-guided hemorrhoidal dearterialization with laser (HeLP): a prospective analysis of data from a multicenter trial. Tech Coloproctol; 25:635-643

Secondary Outcome Measures

Success Rate 2 [12 months follow-up]
To establish the success rate in terms of partial or complete resolution of the symptoms Symptoms will be assessed using the Hemorrhoidal Disease Symptom Score described by Rorvik HD
Number of outpatient sessions [12 months follow-up]
To evaluate the average number of outpatient sessions necessary for treatment success
Rate of complications - adverse events [6 months follow-up]
To establish the rate of complications
Quality of Life [12 months follow-up]
Short Health Scale HD 4 questions with 7-point Liker scale each (1 = very dissatisfied, 7 = very satisfied) Minimum = 4 Maximum = 28
To establish the average time required to reach autonomy [12 months follow-up]
We considered autonomy as the return to normal activity: it includes also the return to work apart from cases of retired patients in which we considered it as the complete return to daily activities

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients above 18 and below 75 years of age with a confirmed diagnosis of second-degree HD (proctological examination, proctoscopy and, if required, colonoscopy)
Patients who report persistent perianal bleeding as a typical symptom of second-degree HD
Informed consent from each patient must be obtained
Participating centres will be asked to confirm that they have gained formal approval at their site

Exclusion Criteria:

Previous anal surgical procedures
Previous sclerotherapy or rubber band ligation in the last 12 months
Positive pregnancy test
Patients with inability to return for postoperative control visits, to sign the informed consent or to fill out the required clinical diary
Breast-feeding
Known allergy to polidocanol
Acute perianal thrombosis
Anal fistula
Anal fissure
Proctitis
Fecal incontinence
Coagulation disorders
Anticoagulant therapy
Known HBV, HCV and HIV infection
Acite Crohn's disease or Ulcerative colitis
Diabetes mellitus I and II
COPD
Any kind of tumour
Previous pelvic radiotherapy